Since the founding of the company, Roche has been developing innovative solutions for a wide range of chronic and life threatening health conditions that continue to revolutionise healthcare. We continue to be committed to developing medicines and diagnostics that improve people’s lives, delivering rapid, broad and sustainable patient access to our solutions and ultimately transforming healthcare to benefit society and people.


Upcoming Molecules

Trade (Product)
Generic Name Indication Tentative approval Country of origin
Hemlibra Emicizumab Routine prophylaxis to prevent or reduce frequency of bleeding episodes in adults and children ≥ 12 y.o with hemophilia A with FVIII inhibitors May-22 Japan
Rozlytrek Entrectinib Treatment of NTRK fusion-positive, locally advanced or metastatic solid tumor adult and pediatric patients
Treatment of ROS-1 fusion-positive, locally advanced or metastatic NSCLC
Jun-22 USA
Gavreto Pralsetinib Metastatic RET Fusion-positive NSCLC; RET-Mutant Medullary Thryoid Cancer; RET Fusion-positive Thyroid Cancer; Jun-22 USA
PHESGO Pertuzumab / Trastuzumab Fixed Dose Combination Metastatic Brest Cancer & Early Brest Cancer (neoadjuvant & adjuvant) Sep-22 Switzerland
Polivy Polatuzumab vedotin Combination with rituximab and bendamustine is indicated for the treatment of adult patients with diffuse large B-cell lymphoma who have received at least one prior therapy. Sep-22 Switzerland
Evrysdi Risdiplam Spinal muscular atrophy (SMA) Sep-22 Switzerland
Enspryng Satralizumab Treatment of Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Sep-22 Japan
Ronapreve Casirivimab/imdevimab Treatment and prevention of SARS-COV-2 infection Sep-22 Switzerland
Vabysmo Faricimab nAMD - neovascular age-related macular degerneration
DME - Diabetic macular edema
DR - Diaetic rethinopathy (US only)
Sep-23 Germany
Susvimo Ranibizumab PDS neovascular Age related Macular Degenaration (nAMD) Sep-23 Germany
Ocrevus Ocrelizumab Relapsing multiple sclerosis (RMS) & Primary progressive multiple sclerosis (PPMS) Sep-23 Germany
  Mosunetuzumab 3L relapsed/refractory Follicular Lymphoma Sep-23 USA
  Glofitamab 3L+ relapsed/refractory DLBCL Jun-24 USA
Tecentriq SC Atezolizumab NSCLC + all approved IV indications of Tecentriq IV Jun-25 Germany
  Tiragolumab Tiragolumab is indicated in combination with atezolizumab, etoposide and carboplatin for the firrst-line treatment of adult patients with extensive stage small cell lung cancer (ES SCLC) Jun-25 Switzerland
  Giredestrant 2/3L metastatic Breast Cancer (supported by Ph2 trial) Jun-25 Switzerland